GM
GMED.K
—
NYSE
Health Care Equipment & Supplies
Gmed.K
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
16,3 %
ROE
11,8 %
Net margin
18,3 %
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$80,58
Open
$79,10
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Globus Medical Inc. operates as a medical technology company, generating revenue through the sale of orthopedic and spine products, as indicated by its sector classification classification in Health Care Equipment & Supplies.
Business. Globus Medical Inc. operates as a medical technology company, generating revenue through the sale of orthopedic and spine products, as indicated by its sector classification classification in Health Care Equipment & Supplies.
Classification85 %
SectorHealth Care
Industry groupHealth Care Equipment & Supplies
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
JANUS HENDERSON GROUP PLC
largest disclosed fund holder
Profitability→
11,8 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,7 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,4 %−2,7 %−0,9 %
Real Estate−0,7 %+10,9 %−1,3 %
Consumer Staples−0,7 %+2,3 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to GMED.K. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Peers
- DividendDividend USD 1.75/sh2026-09-25 · Bank of America (BAC)
- EarningsQ3 2026 earnings (expected)2026-10-13 · estimated · JPMorgan Chase (JPM)
- EarningsQ3 2026 earnings (expected)2026-10-13 · estimated · Citigroup (C)
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
- Congressional trades
- CongressLisa McClain — Globus Medical, Inc. Class A Common2025-07-10 · Republican · MI · Sale · $1,001 - $15,000
- CongressLisa McClain — Globus Medical, Inc. Class A Common2025-06-24 · Republican · MI · Sale · $1,001 - $15,000
- CongressLisa McClain — Globus Medical, Inc. Class A Common2025-06-17 · Republican · MI · Purchase · $1,001 - $15,000
- CongressJosh Gottheimer — Globus Medical, Inc. Class A Common2025-04-09 · Democrat · NJ · Sale · $1,001 - $15,000
- CongressJosh Gottheimer — Globus Medical, Inc. Class A2023-04-03 · Democrat · NJ · Purchase · $1,001 - $15,000
- CongressJosh Gottheimer — Globus Medical, Inc. Class A2023-02-08 · Democrat · NJ · Sale · $1,001 - $15,000
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Globus Medical Inc. operates as a medical technology company, generating revenue through the sale of orthopedic and spine products, as indicated by its sector classification classification in Health Care Equipment & Supplies.
Classification85 %
SectorHealth Care
Industry groupHealth Care Equipment & Supplies
AI synthesis
GENERATED— missing data
Key takeaways
- Debt-free balance sheet with $4.57B equity and $526M cash provides strong financial flexibility.
- Strong profitability with 11.76% ROE and 10.14% ROA.
- Low dilution and liquidity risk flags indicate stable capital structure.
- Global footprint evidenced by subsidiaries in North America, Europe, South America, and Africa.
- No historical trend data available to assess growth momentum.
- Classification discrepancy exists between sector classification (Health Care) and rule-based (Financials) sources.
Bull / Bear case
analysis pipeline— missing data
In focus — financials by report
Valuation
Market price
$80,58
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
$4.57B
Net cashⓘ
$526.2M
Current ratioⓘ
—
Debt / equityⓘ
—
ROAⓘ
10.1%
ROEⓘ
11.8%
Cash conversionⓘ
140.0%
CapEx / revenueⓘ
5.6%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships22 disclosed relationships · 1 type · extracted from filings & disclosures
Subsidiaries22
EX21:011c15533791EX21:011c15533791Subsidiarie97%
EX21:0ab91f739765EX21:0ab91f739765Subsidiarie97%
EX21:15342133889bEX21:15342133889bSubsidiarie97%
EX21:168869ee2903EX21:168869ee2903Subsidiarie97%
EX21:3521f4195121EX21:3521f4195121Subsidiarie97%
EX21:3b5480955bd8EX21:3b5480955bd8Subsidiarie97%
EX21:44d7bf3107a3EX21:44d7bf3107a3Subsidiarie97%
EX21:4eda5fc64502EX21:4eda5fc64502Subsidiarie97%
EX21:4edf05b422beEX21:4edf05b422beSubsidiarie97%
EX21:5bcb751da641EX21:5bcb751da641Subsidiarie97%
EX21:6e451a4e2f8cEX21:6e451a4e2f8cSubsidiarie97%
EX21:8523a6946728EX21:8523a6946728Subsidiarie97%
EX21:a14a6065375dEX21:a14a6065375dSubsidiarie97%
EX21:a34a05c7064fEX21:a34a05c7064fSubsidiarie97%
EX21:b0fae61ea4e4EX21:b0fae61ea4e4Subsidiarie97%
EX21:bcd7724206dcEX21:bcd7724206dcSubsidiarie97%
EX21:d30e4f264aceEX21:d30e4f264aceSubsidiarie97%
EX21:d5b08072744fEX21:d5b08072744fSubsidiarie97%
EX21:e242d4af2b55EX21:e242d4af2b55Subsidiarie97%
EX21:e8b5de9b5d51EX21:e8b5de9b5d51Subsidiarie97%
EX21:eb99b29af4dfEX21:eb99b29af4dfSubsidiarie97%
EX21:effbc35a3981EX21:effbc35a3981Subsidiarie97%
Supply chain
— missing data
Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 4,74 |
| Revenue | —no estimate | —no estimate | 3,2B USD |
| Operating income | —no estimate | —no estimate | 806,6M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Corporate eventM&A horizon
M&A probabilityconf 3 %
Probability
3 %
Base rate
3 %
Band
—
180-day horizon · target 2027-01-25 · 1,0× base rate
No acquirer candidates identified by the signal model.
Probabilistic model output — not investment advice. · generated 2026-07-29
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution16 analysts
Strong buy2
Buy9
Hold5
Sell0
Strong sell0
12-month price target$104,54 · Median $103,00
Low $80,00High $122,00
Operating income · consensus806,6M USD
EPS surprise
−16,0 %
reported vs consensus · miss
Revenue surprise
−8,2 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$80,00
Mean$104,54
Median$103,00
High$122,00
Spot$80,58
+29.7 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Op Margin16,3 %Above P75
Net Margin18,3 %Above P75
ROE11,8 %Above median
Capex / Rev5,6 %Above P75
D/E0,00Above median
Cash Conv1,40Above median
Corporate actions / M&A
M&A probabilityconf —
Probability
3 %
Base rate
3 %
Band
Low
180-day horizon · target 2027-01-25 · 1,0× base rate
No acquirer candidates identified by the signal model.
Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 245 885 sh10 exercises · 13 grants13 insiders
- Director · Stock Option (Right to Buy Class A Common Stock) → Class A Common StockDisposed 25 000 @ $26,27exercise · 2026-06-05
- Director · Stock Option (Right to Buy Class A Common Stock) → Class A Common StockDisposed 25 000 @ $26,27exercise · 2026-06-04
- EVP, GC, Corporate Secretary · Stock Option (Right to Buy Class A Common Stock) → Class A Common StockDisposed 20 000 @ $43,58exercise · 2026-02-25
- EVP, GC, Corporate Secretary · Stock Option (Right to Buy Class A Common Stock) → Class A Common StockDisposed 10 000 @ $45,64exercise · 2026-02-12
- Senior Vice President, CFO · Stock Option (Right to Buy Class A Common Stock) → Class A Common StockAcquired 30 000 @ $94,15grant · 2026-01-21
- Director · Stock Option (Right to Buy Class A Common Stock) → Class A Common StockAcquired 15 000 @ $94,15grant · 2026-01-21
- Director · Stock Option (Right to Buy Class A Common Stock) → Class A Common StockAcquired 15 000 @ $94,15grant · 2026-01-21
- Director · Stock Option (Right to Buy Class A Common Stock) → Class A Common StockAcquired 15 000 @ $94,15grant · 2026-01-21
- Director · Stock Option (Right to Buy Class A Common Stock) → Class A Common StockAcquired 15 000 @ $94,15grant · 2026-01-21
- Director · Stock Option (Right to Buy Class A Common Stock) → Class A Common StockAcquired 15 000 @ $94,15grant · 2026-01-21
- Director, Executive Chairman, 10% owner · Stock Option (Right to Buy Class A Common Stock) → Class A Common StockAcquired 100 000 @ $94,15grant · 2026-01-21
- Director, President, CEO · Stock Option (Right to Buy Class A Common Stock) → Class A Common StockAcquired 100 000 @ $94,15grant · 2026-01-21
- EVP, GC, Corporate Secretary · Stock Option (Right to Buy Class A Common Stock) → Class A Common StockAcquired 40 000 @ $94,15grant · 2026-01-21
- Director · Stock Option (Right to Buy Class A Common Stock) → Class A Common StockAcquired 15 000 @ $94,15grant · 2026-01-21
- Director · Stock Option (Right to Buy Class A Common Stock) → Class A Common StockAcquired 15 000 @ $94,15grant · 2026-01-21
- Director · Stock Option (Right to Buy Class A Common Stock) → Class A Common StockAcquired 15 000 @ $94,15grant · 2026-01-21
- Director · Stock Option (Right to Buy Class A Common Stock) → Class A Common StockAcquired 15 000 @ $94,15grant · 2026-01-21
- Senior Vice President, CFO · Stock Option (Right to Buy Class A Common Stock) → Class A Common StockDisposed 3 594 @ $51,87exercise · 2026-01-08
- Director, Executive Chairman, 10% owner · Stock Option (Right to Buy Class A Common Stock) → Class A Common StockDisposed 34 375 @ $25,52exercise · 2025-12-08
- Senior Vice President, CFO · Stock Option (Right to Buy Class A Common Stock) → Class A Common StockDisposed 5 000 @ $56,43exercise · 2025-12-01
- Senior Vice President, CFO · Stock Option (Right to Buy Class A Common Stock) → Class A Common StockDisposed 3 646 @ $53,14exercise · 2025-12-01
- SVP, GC, Corporate Secretary · Stock Option (Right to Buy Class A Common Stock) → Class A Common StockDisposed 7 500 @ $25,96exercise · 2025-11-25
- Director · Stock Option (Right to Buy Class A Common Stock) → Class A Common StockDisposed 25 000 @ $25,52exercise · 2025-11-12
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
How metrics are computed
- Cash Conversion Ratiooperating_cash_flow / net_income
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Capex To Revenuecapital_expenditure / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
Source documents
- GLOBUS MEDICAL, INC. Market data — financials · 2026-07-29
- reconciler_enqueue (reconciler) on GMED.K · 2026-07-29
- GMED.K HA canonical relationships · 2026-07-29
Ownership & reference
Top holders
- Institutional Investor · as of 2026-03-310,33 %$657M
- Funds · as of 2026-03-310,06 %$372M
- Investment Managers · as of 2026-03-310,05 %$153M
- Investment Managers · as of 2026-03-310,04 %$79M
- Investment Managers · as of 2026-03-310,03 %$72M
- Investment Managers · as of 2026-03-310,03 %$152M
- Investment Managers · as of 2026-03-310,02 %$35M
- Investment Managers · as of 2026-03-310,02 %$26M
- Investment Managers · as of 2026-03-310,02 %$107M
- Investment Managers · as of 2024-06-300,02 %$708M
- Investment Managers · as of 2024-12-310,01 %$53M
- Investment Managers · as of 2025-12-310,01 %$921M
- Investment Managers · as of 2026-03-310,01 %$98M
- Institutional Investor · as of 2026-03-310,01 %$64M
- Investment Managers · as of 2026-03-310,01 %$21M
- Investment Managers · as of 2026-03-310,01 %$182M
- Investment Managers · as of 2026-03-310,01 %$309M
- Investment Managers · as of 2026-03-310,01 %$74M
- Brokerage Firms · as of 2026-03-310,01 %$29M
- Investment Managers · as of 2026-03-310,01 %$16M
- Investment Managers · as of 2026-03-310,01 %$47M
- Institutional Investor · as of 2026-03-310,01 %$20M
- Investment Managers · as of 2026-03-310,01 %$49M
- Investment Managers · as of 2026-03-310,01 %$0M
- Brokerage Firms · as of 2026-03-310,01 %$28M
- Investment Managers · as of 2026-03-310,01 %$91M
- Institutional Investor · as of 2026-03-310,00 %$17M
- Investment Managers · as of 2026-03-310,00 %$12M
- Institutional Investor · as of 2026-03-310,00 %$6M
- Institutional Investor · as of 2026-03-310,00 %$52M
- Institutional Investor · as of 2022-09-300,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$6M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Leadership
- David C. PaulExecutive Chairman of the Board
Insider activity
Net selling0 buys · 9 sellsnet -$10,2M6 insiders · last 365d
- Director · Class A Common StockOther 2 500 · 2026-07-27
- Director · Class A Common StockSold 25 000 @ $80,76$2,0M · 2026-06-05
- Director · Class A Common StockOther 25 000 @ $26,27$657K · 2026-06-05
- Director · Class A Common StockOther 25 000 @ $26,27$657K · 2026-06-04
- EVP, GC, Corporate Secretary · Class A Common StockOther 20 000 @ $43,58$872K · 2026-02-25
- EVP, GC, Corporate Secretary · Class A Common StockSold 20 000 @ $94,50$1,9M · 2026-02-25
- EVP, GC, Corporate Secretary · Class A Common StockSold 10 000 @ $87,67$877K · 2026-02-12
- EVP, GC, Corporate Secretary · Class A Common StockOther 10 000 @ $45,64$456K · 2026-02-12
- Senior Vice President, CFO · Class A Common StockOther 3 594 @ $51,87$186K · 2026-01-08
- Senior Vice President, CFO · Class A Common StockSold 3 594 @ $101,10$363K · 2026-01-08
- Director · Class A Common StockSold 2 000 @ $101,10$202K · 2026-01-08
- Director · Class A Common StockSold 4 000 @ $88,85$355K · 2025-12-12
- Director, Executive Chairman, 10% owner · Class A Common StockOther 34 375 @ $25,52$877K · 2025-12-08
- Senior Vice President, CFO · Class A Common StockOther 4 896 @ $63,68$312K · 2025-12-01
- Senior Vice President, CFO · Class A Common StockOther 3 646 @ $53,14$194K · 2025-12-01
- Senior Vice President, CFO · Class A Common StockOther 5 000 @ $56,43$282K · 2025-12-01
- Senior Vice President, CFO · Class A Common StockOther 5 000 @ $64,44$322K · 2025-12-01
- Senior Vice President, CFO · Class A Common StockSold 18 542 @ $90,00$1,7M · 2025-12-01
- SVP, GC, Corporate Secretary · Class A Common StockOther 7 500 @ $25,96$195K · 2025-11-25
- SVP, GC, Corporate Secretary · Class A Common StockSold 7 500 @ $90,00$675K · 2025-11-25
- Director · Class A Common StockOther 25 000 @ $25,52$638K · 2025-11-12
- Director · Class A Common StockSold 25 000 @ $86,00$2,2M · 2025-11-12
Short positioning
7.1Mshares short-4.6% vs prior
3.5days to cover
62.6%short of daily vol
2.8Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
GMED.KCanonical
NYSE · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Relationship graph
This companyPeerSectorSubsidiaries
Evidence & claims
From filings & derived data- Cash & equivalents (annual): USD 526.16MUnknown
- Shareholders' equity (annual): USD 4.57BUnknown
- Total liabilities (annual): USD 729.51MUnknown
- Pre-tax income (annual): USD 605.07MUnknown
- Cost of revenue (annual): USD 957.8MUnknown
- Operating cash flow (annual): USD 753.45MUnknown
- Current liabilities (annual): USD 498.5MUnknown
- Total assets (annual): USD 5.3BUnknown
- Current assets (annual): USD 2.13BUnknown
- Net income (annual): USD 537.87MUnknown
- Revenue (annual): USD 2.94BUnknown
- EPS (basic) (annual): USD-PER-SHARES 4Unknown
- EPS (diluted) (annual): USD-PER-SHARES 4Unknown
- Operating income (annual): USD 479.82MUnknown
- Capex (annual): USD 164.68MUnknown
- R&D expense (annual): USD 147.25MUnknown
- Shareholders' equity (annual): USD 4.18BUnknown
- Total assets (annual): USD 5.25BUnknown
- Cost of revenue (annual): USD 1.04BUnknown
- Net income (annual): USD 102.98MUnknown
- Current assets (annual): USD 2.18BUnknown
- Operating income (annual): USD 165.99MUnknown
- Current liabilities (annual): USD 855.91MUnknown
- EPS (diluted) (annual): USD-PER-SHARES 1Unknown
Showing 24 of 32 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-07-27INSIDERDavidar David D transacted 2.5k sh Class A Common Stock — Director
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)
2026-06-30 03:14 UTCHOLDERInstitutional holding changed
2026-06-30 03:14 UTCHOLDER1 institutional position change flagged (1 major)
2026-06-28 03:14 UTCHOLDERInstitutional holding changed
2026-06-28 03:14 UTCHOLDER1 institutional position change flagged (1 major)
2026-06-26 03:13 UTCHOLDERInstitutional holding changed
2026-06-26 03:13 UTCHOLDER1 institutional position change flagged (1 major)
2026-06-25 03:10 UTCHOLDERInstitutional holding changed
2026-06-25 03:10 UTCHOLDER1 institutional position change flagged (1 major)
2026-06-24 03:12 UTCHOLDERInstitutional holding changed
2026-06-24 03:12 UTCHOLDERInstitutional holding changed
2026-06-24 03:12 UTCHOLDER2 institutional position changes flagged (2 major)
2026-06-23 03:11 UTCHOLDERInstitutional holding changed
2026-06-23 03:11 UTCHOLDER1 institutional position change flagged (1 major)
2026-06-21 02:57 UTCHOLDERInstitutional holding changed
2026-06-21 02:57 UTCHOLDER1 institutional position change flagged (1 major)
2026-06-05 00:00 UTCINSIDER5 insider transactions — 2026-06 · net sell $706k 2 derivative
2026-06-05 00:00 UTCINSIDER5 insider transactions — 2026-06 · net sell $706k 2 derivative
2026-06-05INSIDERDavidar David D sold 25.0k sh Class A Common Stock — Director ~$2.02M
2026-06-05INSIDERDavidar David D transacted 25.0k sh Class A Common Stock — Director ~$657k
2026-06-05INSIDERDavidar David D disposed of 25.0k sh Stock Option (Right to Buy Class A Common Stock) — Director
2026-06-04INSIDERRHOADS ANN D transacted 25.0k sh Class A Common Stock — Director ~$657k
2026-06-04INSIDERRHOADS ANN D disposed of 25.0k sh Stock Option (Right to Buy Class A Common Stock) — Director
2026-02-25 00:00 UTCINSIDER6 insider transactions — 2026-02 · net sell $1.4M 2 derivative
2026-02-25 00:00 UTCINSIDER6 insider transactions — 2026-02 · net sell $1.4M 2 derivative
2026-02-25INSIDERHuller Kelly transacted 20.0k sh Class A Common Stock — EVP, GC, Corporate Secretary ~$872k
2026-02-25INSIDERHuller Kelly sold 20.0k sh Class A Common Stock — EVP, GC, Corporate Secretary ~$1.89M
2026-02-25INSIDERHuller Kelly disposed of 20.0k sh Stock Option (Right to Buy Class A Common Stock) — EVP, GC, Corporate Secretary
2026-02-12INSIDERHuller Kelly transacted 10.0k sh Class A Common Stock — EVP, GC, Corporate Secretary ~$456k
2026-02-12INSIDERHuller Kelly sold 10.0k sh Class A Common Stock — EVP, GC, Corporate Secretary ~$877k
2026-02-12INSIDERHuller Kelly disposed of 10.0k sh Stock Option (Right to Buy Class A Common Stock) — EVP, GC, Corporate Secretary
Showing the 40 most recent of 83 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data
Premium coverage